SCHEMBL19979321

SCHEMBL19979321

Cn1nnc2c(C(=O)OCCSSc3ccccn3)ncn2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
PABPC1 P11940 1/20 0.47
KMT2A Q03164 1/20 0.47
CA12 O43570 3/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA9 Q16790 3/20 0.40
ALDH1A1 P00352 3/20 0.34
LMNA P02545 2/20 0.33
HDAC1 Q13547 4/20 0.32
HDAC2 Q92769 4/20 0.32
APP P05067 1/20 0.32
POLB P06746 1/20 0.32
USP2 O75604 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
HSD17B10 Q99714 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19979304 0.79 MEN1 (0.50) MEN1PABPC1KMT2ACA12CA1
SCHEMBL3854103 0.77 MEN1 (0.61) MEN1PABPC1KMT2ACA12CA1
SCHEMBL10645126 0.75 KMT2A (0.56) MEN1PABPC1KMT2ACA12CA1
SCHEMBL3851646 0.75 MEN1 (0.59) MEN1PABPC1KMT2ACA12CA1
SCHEMBL19979299 0.75 MEN1 (0.59) MEN1PABPC1KMT2ACA12CA1
SCHEMBL19979300 0.75 MEN1 (0.46) MEN1PABPC1KMT2ACA12CA1
SCHEMBL19979293 0.74 MEN1 (0.55) MEN1PABPC1KMT2ACA12CA1
SCHEMBL3855001 0.74 MEN1 (0.64) MEN1PABPC1KMT2ACA12CA1
SCHEMBL19979295 0.74 MEN1 (0.57) MEN1PABPC1KMT2ACA12CA1
SCHEMBL21726067 0.74 MEN1 (0.57) MEN1PABPC1KMT2ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912709-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease UNIVERSITY OF MASSACHUSETTS (US) 2024-02-27 US disclosed
US-11912709-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease UNIVERSITY OF MASSACHUSETTS (US) 2024-02-27 US disclosed
US-20210198265-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE UNIVERSITY OF MASSACHUSETTS 2021-07-01 US disclosed
US-10995094-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease THE UNIVERSITY OF MASSACHUSETTS (US) 2021-05-04 US disclosed
US-20200140448-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE NATIONAL SCIENCE FOUNDATION 2020-05-07 US disclosed
US-10562901-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease THE UNIVERSITY OF MASSACHUSETTS (US) 2020-02-18 US disclosed
US-20180079754-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE NATIONAL SCIENCE FOUNDATION 2018-03-22 US disclosed
US-20180079754-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE NATIONAL SCIENCE FOUNDATION 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912709-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885
US-20210198265-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885
US-20200140448-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885
US-10562901-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885
US-20180079754-A1 TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885
US-10995094-B2 Temozolomide compounds, polymers prepared therefrom, and method of treating a disease PBRM1, MGMT, TOP1 MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.